Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
The Tohoku Journal of Experimental Medicine|August 6, 2013
Yolk sac tumor of the ovary: a retrospective multicenter study of 33 Japanese women by Tohoku Gynecologic Cancer Unit (TGCU)Takanobu Kojimahara, Kenji Nakahara, Tadao Takano, et al.
International Journal of Clinical Oncology|January 17, 2026
Efficacy and safety of bevacizumab-combined single-agent chemotherapy for platinum-resistant ovarian cancer that recurred during PARP inhibitor treatmentEriko Takatori, Tadahiro Shoji, Ami Jo, et al.
International Journal of Clinical Oncology|June 26, 2016
Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky massTadahiro Shoji, Eriko Takatori, Yoko Furutake, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 19, 2011
Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study)Tadahiro Shoji, Eriko Takatori, Hideo Omi, et al.
International Cancer Conference Journal|July 23, 2026
Clinical utility of diagnostic laparoscopy for ovarian metastasis from breast cancer in a BRCA1-mutated patient with hereditary breast and ovarian cancer syndrome: a case report and literature reviewSho Sato, Mitsumasa Osakabe, Shingo Hosomi, et al.
International Journal of Clinical Oncology|August 7, 2026
Benefits of PARP inhibitor rechallenge in patients with platinum-sensitive recurrent ovarian cancer previously treated with a PARP inhibitor: a multicenter retrospective studyAmi Jo, Tadahiro Shoji, Ayaka Kitamura, et al.
Molecular and Clinical Oncology|December 14, 2019
Clinical and reproductive outcomes of fertility-sparing surgery in stage I epithelial ovarian cancerTakafumi Watanabe, Shu Soeda, Hiroshi Nishiyama, et al.
Cancer Science|August 25, 2017
Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancerShin Nishio, Munetaka Takekuma, Satoshi Takeuchi, et al.
Cancer Chemotherapy and Pharmacology|June 29, 2017
A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)Tadahiro Shoji, Eriko Takatori, Hideo Omi, et al.
Archives of Gynecology and Obstetrics|November 17, 2025
Prognostic factors for malignant tumors arising from mature cystic teratomas: a study involving the Kansai Clinical Oncology Group (KCOG-G1305s study)Fuminori Ito, Mototsugu Shimokawa, Atsushi Sugiura, et al.
Pageof 9